Genentech

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Conference call, Expansion, New Drug Application, Suite, Food, FDA, Growth, Shanda, Bupivacaine, Novo Nordisk, Conference, Genentech, GAAP, Roche, Pain management, Therapy, Patient, Cancer

TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023.

Key Points: 
  • ET —
    TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023.
  • Fourth quarter 2023 iovera° net product sales were $6.0 million, a 32% increase over the $4.6 million reported in the fourth quarter of 2022.
  • Total operating expenses were $148.1 million in the fourth quarter of 2023, versus the $181.8 million reported for the fourth quarter of 2022.
  • Cash provided by operations was $47.6 million in the fourth quarter of 2023, compared to $42.0 million in the fourth quarter of 2022.

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Wednesday, February 28, 2024
Real-World Evidence, Cohort, KNSA, C-reactive protein, Rheumatoid factor, Recurrence, Investment, Telephone, Partnership, Growth, ID, Joint, Genentech, Roche, Rheumatoid arthritis, American College, Webcast, Patient, Pericarditis, Paradigm, Prescription, CD40, Pharmaceutical industry

HAMILTON, Bermuda, Feb. 28, 2024 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial results and recent portfolio execution.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million for the fourth quarter of 2022.
  • Net income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million for the fourth quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio execution.

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, February 22, 2024
Breast cancer, BID, Genentech, Research, Fulvestrant, Investment, HR, Discovery, Allosteric regulation, Completeness, Therapy, Patient, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights.

Key Points: 
  • “We are very pleased with the RLY-2608 data disclosed to-date and how its clinical profile continued to mature throughout last year.
  • Revenue: There was no material revenue for the fourth quarter of 2023 or 2022.
  • Revenue was $25.5 million for the full year 2023, as compared to $1.4 million for the full year 2022.
  • G&A Expenses: General and administrative expenses were $16.8 million for the fourth quarter of 2023, as compared to $16.4 million for the fourth quarter of 2022.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
Health, Stem Cells, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Spinal cord, University, CIRM, Roche, Delivery, Interest, Expense, Partnership, Food, Inda, Genentech, Geographic atrophy, Therapy, Webcast, AMD, Patient, Drug discovery, Congress, Survival, G&A, IND, Trial of the century, Research, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

Helix Appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life Sciences

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Genetics, Health, Doctor of Philosophy, Genomics, Drug development, Genentech, Patient, Multimedia, SVP, Management

Helix , the leading population genomics company in the nation, today announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences.

Key Points: 
  • Helix , the leading population genomics company in the nation, today announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences.
  • Kalvaria will oversee partnerships leveraging the unique and growing clinico-genomic datasets of Helix with life sciences customers.
  • Kalvaria also served in leadership roles at Verana Health, Flatiron Health, and Genentech.
  • Helix is committed to partnering with life science companies to leverage real-world clinico-genomic data across the drug development lifecycle.”

Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, FDA, Health, Pharmaceutical, Oncology, Other Science, Research, Artificial Intelligence, Science, Clinical Trials, NSCLC, Cancer, Clonal hematopoiesis, Doctor of Philosophy, Artificial intelligence, Immunotherapy, Neoplasm, Pathology, TME, PCG, Effectiveness, AACR, Interface, Data, HER2, Lung cancer, Genentech, Flatiron, Roche, Biomarker, Tumor microenvironment, Abstract, Patient, Survival, Foundation Medicine, Plasma, DNA, Medical imaging

Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

Key Points: 
  • Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
  • ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy.
  • These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning.
  • Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

Seek Labs Welcomes Cindy Dunkle, Accomplished HR Leader with Extensive Life Sciences Experience, to Board of Directors

Retrieved on: 
Tuesday, February 27, 2024
Health, Infectious Diseases, Other Science, Research, Science, Pharmaceutical, Biotechnology, Therapy, Acquisition, Week, CRISPR, Poverty, Seek, Metropolitan, Management, IPO, Metropolitan State University, Safety, Genentech, Environmental health, Patient, Adverum Biotechnologies, Woman

Dunkle brings decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.

Key Points: 
  • Dunkle brings decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.
  • Dunkle is widely recognized for her profound understanding of human capital management in the life sciences sector.
  • Jared Bauer, CEO, expressed his enthusiasm to have Dunkle join Seek Labs’ Board: “We are thrilled to have Cindy Dunkle join our Board of Directors.
  • "I am honored to join Seek Labs’ Board of Directors at a pivotal moment as the company continues to grow and expand its footprint in the life sciences and biotechnology industry,” said Cindy Dunkle.

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

Retrieved on: 
Monday, March 4, 2024
Neoplasm, Biotechnology, Senior, Indiana University, Food, Health, Drug development, Spacecraft, ADC, Stanford University, Doctor of Philosophy, University, Genentech, Safety, Roche, Therapy, Immunology, Food and Drug Administration, Abstract, Patient, Internal medicine, Oncology, Rush Medical College, Vanderbilt University, Publication, Mirati Therapeutics, Cancer, Pharmaceutical industry

"We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.

Key Points: 
  • "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.
  • On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies."
  • Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics.
  • Dr. Sandler is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia.

Omalizumab Increases the Reaction Threshold for Peanut and Other Common Food Allergies

Retrieved on: 
Sunday, February 25, 2024
Infection, Anxiety, AAAAI, Research, Food allergy, Multimedia, NIAID, MD, NIH, Quality of life, Immunoglobulin E, Asthma, Novartis, Annual general meeting, Genentech, Roche, Patient, Journal, Food, American Academy

WASHINGTON, Feb. 25, 2024 /PRNewswire-PRWeb/ -- Sixteen weeks of omalizumab results in a higher tolerated threshold for multiple food allergies according to new research presented today at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and published in the New England Journal of Medicine.

Key Points: 
  • "Food allergies affect millions of individuals in the U.S., and those impacted face a daily threat of life-threatening reactions.
  • To remain safe, constant vigilance is required and even then, accidental exposures are very common," said Dr. Robert A.
  • "The OUtMATCH study demonstrated that omalizumab (Xolair) significantly increased the threshold for reaction in most patients for peanut and the six other foods studied, enough to provide real protection against small, accidental exposures.
  • As food allergies are common, this study highlights a valuable option for safe and effective food allergy treatment.